MedTrace Logo

Hepatitis B Virus HBeAg-negative Genotype D Patients and Hepatocellular Carcinoma

NCT02025842 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 306

Last updated 2014-01-01

No results posted yet for this study

Summary

To evaluate the impact of liver fibrosis and other variables \[e.g., age, sex, virological response (VR), and previous resistance to nucleoside/nucleotide analogue (NUC) therapy\] on Hepatocellular carcinoma incidence in an Italian population of genotype D HBeAg-negative CHB patients treated with long-term NUC therapy.

Conditions

Sponsors & Collaborators

  • Azienda Ospedaliera San Camillo Forlanini

    lead OTHER

Principal Investigators

  • Adriano M Pellicelli, MD · AO San Camillo Forlanini

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-01-31
Primary Completion
2013-12-31
Completion
2013-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02025842 on ClinicalTrials.gov